An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of GR37547 Ciprofloxacin 500 mg Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Participants Under Fasting Conditions
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ciprofloxacin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 14 Aug 2017 Planned primary completion date changed from 3 Aug 2017 to 25 Aug 2017.
- 14 Aug 2017 Status changed from not yet recruiting to recruiting.
- 23 May 2017 New trial record